Actualités et événements

Halo Pharma Emerges as Standalone CDMO Following Siegfried Acquisition of Noramco Independent CDMO positioned for growth in sterile injectables and other complex drug product formats Over $30 million investment plan underway to establish sterile vial, prefilled syringe, and cartridge manufacturing in Whippany, NJ Lee Karras (previously CEO of Noramco) named Halo Pharma’s CEO to lead next phase of expansion Whippany, NJ – May 1, 2026 – Halo Pharma (the “Company”), a leading CDMO partner to the pharmaceutical industry and previous division of Noramco Group, is now operating as a standalone business following Siegfried’s acquisition of Noramco Group’s small molecule API assets. Owned and supported by funds advised by SK Capital, the Company serves as a dedicated, specialized platform focused on developing and manufacturing products for its pharmaceutical customers. Halo Pharma has invested heavily to support its active expansion into sterile product development and fill/finish services to support growing customer demand. “Building on decades of supporting pharmaceutical and healthcare clients, Halo Pharma is entering an exciting new phase as an independent CDMO,” said Lee Karras, CEO of Halo Pharma. “We are focused on expanding our capabilities to meet evolving customer needs, including the launch of sterile injectable manufacturing at our Whippany,

Apotex Announces Strategic U.S. Sterile Filling Partnership with Halo Pharmaceuticals Weston, Florida and Whippany, New Jersey — April 14, 2026 – Apotex Corp. today announced that it has secured a strategic sterile filling partnership with Halo Pharmaceuticals through an investment that provides Apotex with access to a significant portion of the overall sterile injectable filling capacity currently being installed and qualified at Halo’s Whippany, New Jersey facility. This access is intended to support Apotex’s sterile injectable manufacturing network and signals a strong investment in sterile U.S.-based manufacturing, infrastructure and research and development capabilities. The partnership aligns with Apotex’s Journey of Health strategy and its broader focus on strengthening domestic manufacturing operations. The arrangement enables Apotex to access near-term sterile filling capacity and offers an alternative to a greenfield development approach, providing operational flexibility as part of its global manufacturing strategy. Halo Pharmaceuticals is a strategically aligned organization providing development and manufacturing services across a range of dosage forms, including sterile injectable formats. Through this collaboration, Apotex brings its strong sterile processing experience, regulatory readiness expertise, and commercialization capabilities while securing access to vial and pre-filled syringe filling capacity. The partnership builds upon the existing Apotex-Halo relationship, which currently includes non-sterile

Halo Pharma Executive Chairman Lee Karras says escalating equipment and component costs are the two biggest challenges facing parenteral/sterile drug product manufacturers.

Whippany, NJ – January 27, 2026 SK Capital Partners have signed a definitive agreement to divest the Noramco API related assets in a sale to Siegfried (Zofingen Switzerland) The transaction is subject to customary closing conditions and regulatory approvals Halo Pharma, with sites in Whippany, NJ and Mirabel QC, will remain as a stand-alone company with a focus on growth as a drug product contract development and manufacturing organization (CDMO) Lee Karras will become CEO of Halo Pharma after the transaction closes The divestiture allows for more focus on drug product services in North America as Halo expands into more complex drug product manufacturing services such as sterile fill/finish Halo Pharma, a leading CDMO specializing in drug product pharmaceutical development and manufacturing services, will become a stand-alone business as a result of the sale of the Noramco API and associated businesses to Siegfried. Halo Pharma was purchased by the Noramco Group from Cambrex in 2023. With the sale of the API related assets of the Noramco Group, Halo will serve as a dedicated platform for drug product CDMO services. Halo’s sterile CDMO business is expected to be online in the second half of 2026 with a state-of-the-art Groninger UFVN FlexFill

Whippany, NJ – December 16, 2025 New addition enhances manufacturing continuity and supports seamless progression from early-phase development to late-stage production Macro-Pactor® to be online in Q1 2026 Halo Pharma, a leading CDMO specializing in pharmaceutical development and manufacturing services, is expanding its manufacturing capabilities at its Whippany, New Jersey facility with the addition of a Gerteis Macro-Pactor®, a versatile roller compactor that enhances the company’s ability to manage complex formulations, improve process efficiency, and deliver consistent solid-dose pharmaceutical products. The investment reinforces Halo Pharma’s position as a reliable partner for both development and commercial manufacturing as it allows for seamless scale up from Halo Whippany’s Gerties Mini-Pactor® currently used for development, clinical and small scall commercial manufacturing. The Macro-Pactor is expected to be online in the first quarter of 2026. Its high throughput, superior dry-granulation performance, improved powder flow, and reduced variability will significantly expand Halo Pharma’s dry-granulation capabilities. It will improve formulation flexibility, process predictability, and granule quality. This technology is especially beneficial for the development of moisture-sensitive APIs, high-drug-load formulations, poor-flowing powders, potent compounds, and modified-release products within Halo Pharma’s portfolio. “One of the major advantages of adding the Macro-Pactor is that the process parameters established during

Whippany, NJ – 14 octobre 2025 – Laurent Malgouyres rejoint Halo fort de plus de 14 ans d'expérience opérationnelle dans l'industrie pharmaceutique. En tant que directeur de site, il supervisera les opérations du site de production cGMP de Halo à Mirabel. Halo Pharma, une CDMO de premier plan spécialisée dans le développement et la fabrication de produits pharmaceutiques, a nommé Laurent Malgouyres au poste de directeur de son site cGMP de Mirabel, au Québec, Canada. Dans ses nouvelles fonctions, M. Malgouyres supervisera la production, la qualité et la performance globale du site. Fort de plus de 14 ans d'expérience dans l'industrie pharmaceutique, il occupait récemment le poste de vice-président des opérations chez Omega Laboratories/Juno Pharmaceuticals au Canada. Auparavant, il a occupé des postes de direction chez Pharmascience, où il a géré des sites agréés par la FDA et Santé Canada employant plus de 200 personnes. Tout au long de sa carrière, il a mené avec succès des initiatives visant à accroître la capacité de production, à mettre en œuvre des processus d'efficacité opérationnelle et à réaliser d'importants projets d'investissement. “ Laurent a fait ses preuves en matière de création d'équipes autonomes et performantes, tout en favorisant une culture d'excellence opérationnelle, d'amélioration continue et de développement humain, valeurs qui correspondent à nos convictions et objectifs fondamentaux chez Halo Pharma ”, déclare Lee Karras, PDG de Noramco, société mère de Halo Pharma. “ Son expérience et sa vision seront essentielles à la poursuite de notre développement. »